Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257033 · ClinicalTrials.gov registry record · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
A Phase 3 study of Locally Advanced Pancreatic Cancer, sponsored by RenovoRx.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT03257033 is a Phase 3 study of Locally Advanced Pancreatic Cancer that is actively recruiting participants, run by RenovoRx. The registered enrollment target is 190 participants, above the 58-participant average among 3 other Locally Advanced Pancreatic Cancer trials with a reported enrollment target (228% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03257033, a Phase 3 study of Locally Advanced Pancreatic Cancer, is actively recruiting participants, sponsored by RenovoRx.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG nab-paclitaxel
- DEVICE RenovoCath
Study Locations (20)
Florida
- 21st Century Oncology - Fort Myers
- Miami Cancer Center - Miami
- Sarasota Memorial Health Care System - Sarasota
- Moffitt Cancer Center - Tampa
- ASCLEPES Research Centers - Weeki Wachee
California
- VA Loma Linda Healthcare System - Loma Linda
- Sutter Cancer Center Sacramento - Sacramento
Colorado
- Rocky Mountain Cancer Centers - Denver
- Comprehensive Cancer Care and Research Institute of Colorado, CCCRIC - Englewood
District of Columbia
- Sibley Memorial Hospital - a member of Johns Hopkins medicine - Washington D.C.
- Georgetown University - Washington D.C.
Louisiana
- Ochsner Clinic Foundation - New Orleans
- LSU Health Shreveport - Shreveport
New Jersey
- MD Anderson Cancer Center at Cooper Hospital - Camden
- Atlantic Health System - Morristown Medical Center - Morristown
Georgia
- Piedmont-Columbus Regional - John B. Amos Cancer Center - Columbus
Iowa
- University of Iowa Hospitals and Clinics - Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257033
The ClinicalTrials.gov registry entry for NCT03257033 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 58-participant average among 3 other Locally Advanced Pancreatic Cancer trials with a reported enrollment target (228% higher). The listed sponsor is RenovoRx, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT03257033 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03257033 about?
NCT03257033 is a clinical study titled "Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC". The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
What is the current status of trial NCT03257033?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2018-03-12. Estimated completion is 2026-09.
What conditions does trial NCT03257033 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT03257033?
The interventions under investigation include: Gemcitabine (DRUG), nab-paclitaxel (DRUG), RenovoCath (DEVICE).
Who is sponsoring clinical trial NCT03257033?
This trial is sponsored by RenovoRx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03257033 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
RECRUITING · NA
-
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.